December 23, 2020

Planning for COVID Vaccines and Costs

“These drugs and therapeutics were developed with significant federal investment,” said Elizabeth Mitchell, chief executive officer of the Pacific Business Group on Health, a member of the employer group. “We think that needs to be reflected in the pricing.”

From the article: “The dream of Covid-19 vaccines is coming closer to reality as Operation Warp Speed officials said that U.S. states’ plans to roll out a shot from Pfizer are due Friday.

The U.S. is ready to ship 6.4 million doses of the vaccine from Pfizer and partner BioNTech as soon as the Food and Drug Administration clears it, said Gus Perna, chief operations officer of the federal drugs and vaccines accelerator. That could come as soon as mid-December.

Anticipation is mounting for Covid-19 vaccines developed in less than a year to battle the pandemic that’s strangling economies worldwide. The Pfizer vaccine will be considered by FDA advisers for emergency authorization Dec. 10, and U.K. drug regulators have already cleared it.

Meanwhile, U.S. employers are increasingly concerned about their share of treatment costs for hospitalized Covid patients who currently number more than 100,000. Employers’ Prescription for Affordable Drugs, a coalition of companies and other employers, cited Gilead Sciences’ remdesivir antiviral as an example of an overpriced Covid-19 therapy.”

Read the full article on Bloomberg News here.

Read about Planning for COVID Vaccines and Costs via Bloomberg   (opens in new window)